Abstracts tagged "Psoriatic arthritis"

Abstract Number: 0469 • ACR Convergence 2021
Imaging Characteristics in Patients with Spondyloarthritis Using a Novel Heel Enthesitis Magnetic Resonance Imaging Scoring (HEMRIS) System: Post-hoc Analysis of a Phase 3 Secukinumab Trial
Xenofon Baraliakos¹, Philipp Sewerin², Eugenio De Miguel³, Effie Pournara⁴, Christine Kleinmond⁵, Ankita Shekhawat⁶, Annette Wiedon⁷ and Frank Behrens⁸, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Department and Hiller Research Unit of Rheumatology, Heinrich Heine University Duesseldorf, Duesseldorf, Germany, ³Hospital Universitario La Paz, Madrid, Spain, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵ClinProject GmbH, Eurasburg, Germany, ⁶Novartis Healthcare Private Limited, Hyderabad, India, ⁷Novartis Pharma GmbH, Nürnberg, Germany, ⁸Rheumatology & Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Frankfurt/Main, Germany
Background/Purpose: The heel is a frequently affected anatomical site for enthesitis in spondyloarthritis (SpA).1 Recently, the Outcome Measures in Rheumatology (OMERACT) group developed and validated…
Abstract Number: 0822 • ACR Convergence 2021
Local Tolerance of GP2017, an Adalimumab Biosimilar with Low Citrate Concentration Formulation, in Healthy Volunteers and Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis
Piotr Wiland¹, Andrew Blauvelt², Lena Lemke³, Oliver von Richter⁴, Alison Balfour⁴, Fabricio Furlan⁴ and Norman Gaylis⁵, ¹Department of Rheumatology and Internal Medicine, Medical University, Wroclaw, Poland, ²Oregon Medical Research Center, Portland, ³Hexal AG (A Sandoz company), Holzkirchen,Germany, Holzkirchen, Germany, ⁴Hexal AG (A Sandoz company), Holzkirchen, Germany, Holzkirchen, Germany, ⁵Arthritis and Rheumatic Disease Specialties, Aventura, FL
Background/Purpose: Adalimumab (ADL) can be self-administered every 2 weeks as a subcutaneous (s.c.) injection in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and psoriasis…
Abstract Number: 1315 • ACR Convergence 2021
The Best Cardiovascular Risk Algorithm to Predict the Presence of Carotid Plaque in Psoriatic Arthritis Patients
Natalia Guajardo-Jauregui, Iris Colunga-Pedraza, Jose Azpiri-Lopez, Dionicio Galarza-Delgado, Alejandra Rodriguez-Romero, Diana Flores-Alvarado, Julieta Loya-Acosta, Alejandro Meza-Garza, Jesus Cardenas-de La Garza, Salvador Lugo-Perez and Jessica Castillo-Treviño, Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico
Background/Purpose: Systemic inflammation in psoriatic arthritis (PsA) patients accelerates the process of atherosclerosis; this increases the risk of presenting a major cardiovascular (CV) event than…
Abstract Number: 1336 • ACR Convergence 2021
Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19-Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis
Iain McInnes¹, Proton Rahman², Alice Gottlieb³, Elizabeth Hsia⁴, Alexa Kollmeier⁵, Xie Xu⁴, Shihong Sheng⁴, Yusang Jiang⁴, May Shawi⁶, Soumya Chakravarty⁷, Désirée van der Heijde⁸ and Philip Mease⁹, ¹University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, ²Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC, La Jolla, CA, ⁶Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁷Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, ⁸Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ⁹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA
Background/Purpose: Guselkumab (GUS), an anti-IL-23p19-subunit mAb dosed every 4 or 8 weeks (Q4W or Q8W), demonstrated efficacy for joint and skin symptoms, inhibition of structural…
Abstract Number: 1353 • ACR Convergence 2021
Whole Blood Transcriptional Changes Following Treatment with Filgotinib in Patients with Psoriatic Arthritis
Dafna Gladman¹, Yihua Liu², Oh Kyu Yoon², Mona Trivedi², René Galien³, Robin Besuyen⁴, Vlad Malkov², Angie Hertz² and Vinod Chandran¹, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²Gilead Sciences, Foster City, CA, ³Galapagos NV, Romainvulle, France, ⁴Galapagos BV, Leiden, Netherlands
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory autoimmune disease characterized by musculoskeletal and skin inflammation. Selective inhibition of Janus kinase 1 (JAK1) has the…
Abstract Number: 1713 • ACR Convergence 2021
Risk of Serious Infections in Offspring Exposed in Utero to Ustekinumab or Vedolizumab
Jonah Gorodensky¹, Sasha Bernatsky¹, Waqqas Afif¹, Yvan St-Pierre², Kristian Filion¹ and Evelyne Vinet³, ¹McGill University, Montréal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Ustekinumab, an IL-12/23 inhibitor, is indicated in adult patients with inflammatory bowel disease (IBD), psoriasis (PsO), and psoriatic arthritis (PsA) and vedolizumab, an α4β7…
Abstract Number: 1788 • ACR Convergence 2021
Improving Care and Capacity Through Capturing and Recording Patient Reported Outcomes with Digital Solutions in Spondyloarthritis
Antoni Chan¹, Kathryn Rigler¹ and Liz van Rossen², ¹Royal Berkshire NHS Foundation Trust, Reading, United Kingdom, ²East Kent NHS Foundation Trust, Kent, United Kingdom
Background/Purpose: Patient-reported outcomes (PROs) have always been at the forefront for the assessment of spondyloarthritis (SpA) which includes axial Spa (axSpA) and psoriatic arthritis (PsA).…
Abstract Number: 1805 • ACR Convergence 2021
Low Rates of Radiographic Progression with 2 Years of Guselkumab (TREMFYA®), a Selective Inhibitor of the Interleukin-23p19 Subunit: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study of Biologic-naïve Patients with Active Psoriatic Arthritis
Philip Mease¹, Alice Gottlieb², Iain McInnes³, Proton Rahman⁴, Alexa Kollmeier⁵, Xie Xu⁶, Yusang Jiang⁶, Shihong Sheng⁶, May Shawi⁷, Soumya Chakravarty⁸, Frederic Lavie⁹ and Désirée van der Heijde¹⁰, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, ⁴Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁵Janssen Research & Development, LLC, La Jolla, CA, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁸Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, ⁹Janssen Global Services, LLC, Horsham, PA, ¹⁰Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands
Background/Purpose: Guselkumab (GUS), an IL-23p19-subunit inhibitor, is efficacious in treating patients (pts) with psoriasis and psoriatic arthritis (PsA). In the Phase 3, double-blind, placebo (PBO)-controlled…
Abstract Number: 1823 • ACR Convergence 2021
Efficacy of Upadacitinib in Patients with Active Psoriatic Arthritis and a Low or High Swollen Joint Count: A Subgroup Analysis of 2 Phase 3 Studies
Laure Gossec¹, Dafna Gladman², Erin McDearmon-Blondell³, Philipp Sewerin⁴, Christopher Ritchlin⁵, Dai Feng⁶, Apinya Lertratanakul⁷, Roberto Ranza⁸, Lai-Shan Tam⁹, Antonio Marchesoni¹⁰, Laura Coates¹¹ and Peter Nash¹², ¹Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³AbbVie Inc., Elmhurst, IL, ⁴Department and Hiller Research Unit of Rheumatology, Heinrich Heine University Duesseldorf, Duesseldorf, Germany, ⁵Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ⁶AbbVie Inc., East Brunswick, NJ, ⁷AbbVie Inc., North Chicago, IL, ⁸Hospital de Clinicas, Universidade Federal de Uberlândia, Uberlandia, MG, Brazil, ⁹Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China (People's Republic), ¹⁰Dipartimento di Reumatologia, ASST Gaetano Pini-CTO, Milano, Italy, ¹¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ¹²Griffith University, Brisbane, Australia
Background/Purpose: Although most patients with psoriatic arthritis (PsA) enrolled in clinical trials have polyarticular arthritis, patients in clinical practice may present with oligoarthritis. Data on…
Abstract Number: 1944 • ACR Convergence 2021
Sustained Remission/Low Disease Activity Is Feasible in the Long Term in Patients with Psoriatic Arthritis Treated with IL-23/12 Inhibition with Ustekinumab (STELARA®) and Tumor Necrosis Factor Inhibitors in a Real-World, Multicenter Study
Josef Smolen¹, Paul Bergmans², Kurt de Vlam³, Elisa Gremese⁴, Beatriz Joven-Ibáñez⁵, Tatiana Korotaeva⁶, Wim Noël⁷, Michael Nurmohamed⁸, Petros Sfikakis⁹, Stefan Siebert¹⁰, Elke Theander¹¹ and Laure Gossec¹², ¹Medical University of Vienna, Vienna, Austria, ²Janssen-Cilag BV, Breda, Netherlands, ³University Hospitals Leuven, Leuven, Belgium, ⁴Fondazione Policlinico A Gemelli-IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, ⁵University Hospital 12 de Octubre, Madrid, Spain, ⁶VA Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁷Janssen Pharmaceutica, HEMAR Department, Beerse, Belgium, ⁸Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ⁹National Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ¹⁰University of Glasgow, Glasgow, United Kingdom, ¹¹Janssen Cilag, Lund, Sweden, ¹²Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France
Background/Purpose: Among treatment options for PsA, IL-23/12 inhibition with ustekinumab (UST) was the first new biologic after TNF inhibitors (TNFi). Few data compare long-term effectiveness…
Abstract Number: 0099 • ACR Convergence 2021
First Results of the BELCOMID Study: BELgian Cohort Study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID)
Kurt de Vlam¹, Jeroen Geldhof², Marie Truyens³, Joao Sabino⁴, Marc ferrante⁴, Jo Lambert³, Hilde lapeere³, Tom hillary⁴, an Van Laethem⁴, Triana Lobaton³, severine vermeire⁴, Barbara Neerinckx¹ and Patrick Verschueren⁵, ¹University Hospitals Leuven, Leuven, Belgium, ²University Hospital Gent, Gent, Belgium, ³university hospital gent, gent, ⁴university hospitals leuven, leuven, ⁵University Hospitals Leuven - KULeuven, Leuven, Belgium
Background/Purpose: It has been suggested that 100% of SARS-CoV2 infections leads to development of specific IgG antibodies that remain detectable for a long period of…
Abstract Number: 0488 • ACR Convergence 2021
Efficacy and Safety of Brepocitinib (Tyrosine Kinase 2/Janus Kinase 1 Inhibitor) for the Treatment of Active Psoriatic Arthritis: Results from a Phase 2b Randomized Controlled Trial
Philip Mease¹, Philip S Helliwell², Paula Silwinska-Stanczyk³, Malgorzata Miakisz⁴, Andrew Ostor⁵, Elena Peeva⁶, Michael Vincent⁶, Vanja Sikirica⁷, Randall Winnette⁸, Ruolun Qiu⁶, Gang Li⁷, Gang Feng⁶, Jean Beebe⁶ and David Martin⁶, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³REUMATIKA – Centrum Reumatologii NZOZ, Warsaw, Poland, ⁴Twoja Przychodnia Centrum Medyczne Nowa Sol, Nowa Sol, Poland, ⁵Monash University, Cabrini Hospital & Emeritus Research, Melbourne, Australia, ⁶Pfizer Inc, Cambridge, MA, ⁷Pfizer Inc, Collegeville, PA, ⁸Pfizer Inc, New York, NY
Background/Purpose: Brepocitinib is a small-molecule tyrosine kinase 2/Janus kinase 1 inhibitor that has shown promising results in an oral formulation for plaque psoriasis and alopecia…
Abstract Number: 0838 • ACR Convergence 2021
Predictors of Treatment for Inflammatory Arthritis with Immune Modulating Medications (IMM) in US Veterans
Tawnie Braaten¹, shaobo Pei², Anitha Rathod², Gopi Penmetsa³, Kevin Douglas⁴, Jodi Walker⁴, Jerry Clewell⁵ and Jessica Walsh⁶, ¹Salt Lake City Veteran Affairs and University of Utah Medical Center, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ⁴AbbVie Inc., North Chicago, IL, ⁵Abbvie Inc, North Chicago, IL, ⁶Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT
Background/Purpose: Non-treatment and treatment delays contribute to suboptimal symptom control and irreversible joint damage in patients with inflammatory arthritis (IA). This investigations objective was to…
Abstract Number: 1317 • ACR Convergence 2021
Impairment of Memory in Axial Spondyloarthritis?
Stefan Kleinert¹, Florian Schuch², Praxedis Rapp², Monika Ronneberger², Joerg Wendler², Patrizia Sternad³, Florian Popp³, Peter Bartz-Bazzanella⁴, Cay Von der Decken⁵, Kirsten Karberg⁶, Georg Gauler⁷, Patrick Wurth⁸, Susanna Späthling-Mestekemper⁹, Christoph Kuhn¹⁰, Mathias Englbrecht¹¹, Wolfgang Vorbrüggen¹², Georg Adler¹³ and Martin Welcker¹⁴, ¹Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany, ²Praxisgemeinschaft Rheumatologie-Nephrologie, Erlangen, Germany, ³Medizinisches Versorgungszentrum für Rheumatologie Dr. M. Welcker GmbH, Planegg, Germany, ⁴Rhein-Maas Klinikum, Wuerselen, Germany, ⁵Klinik für Internistische Rheumatologie, Rhein-Maas-Klinikum, Würselen, Germany, ⁶Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, Berlin, Germany, ⁷rheumapraxis, Osnabrck, Germany, ⁸Rheumatologische Schwerpunktpraxis, Osnabrück, Germany, ⁹Rheumapraxis München, München, Germany, ¹⁰Praxis für Rheumatologie, Karlsruhe, Germany, Karlsruhe, Germany, ¹¹Freelance Healthcare Data Scientist, Eckental, Germany., Eckental, Germany, ¹²Verein zur Förderung der Rheumatologie e.V., Würselen, Germany, ¹³Institut für Studien zur Psychischen Gesundheit (ISPG), Mannheim, Germany, ¹⁴MVZ für Rheumatologie, Planegg, Germany
Background/Purpose: There is certain evidence that neuropsychiatric changes occur in systemic lupus(1) and rheumatoid arthritis (2). However, there is little knowledge about possible cognitive changes…
Abstract Number: 1337 • ACR Convergence 2021
Long-Term Safety Data for IL-12/23 Inhibitor (Ustekinumab) or Tumor Necrosis Factor Inhibitor in Patients with Psoriatic Arthritis from a Real-World Study
Stefan Siebert¹, Paul Bergmans², Kurt de Vlam³, Elisa Gremese⁴, Beatriz Joven-Ibáñez⁵, Tatiana Korotaeva⁶, Wim Noël⁷, Michael Nurmohamed⁸, Petros Sfikakis⁹, Elke Theander¹⁰, Laure Gossec¹¹ and Josef Smolen¹², ¹University of Glasgow, Glasgow, United Kingdom, ²Janssen-Cilag BV, Breda, Netherlands, ³University Hospitals Leuven, Leuven, Belgium, ⁴Fondazione Policlinico A Gemelli-IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, ⁵University Hospital 12 de Octubre, Madrid, Spain, ⁶VA Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁷Janssen Pharmaceutica, HEMAR Department, Beerse, Belgium, ⁸Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ⁹National Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ¹⁰Janssen Cilag, Lund, Sweden, ¹¹Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, ¹²Medical University of Vienna, Vienna, Austria
Background/Purpose: Psoriasis and PsA are associated with multiple comorbidities such as cardiovascular disease and metabolic syndrome. These comorbidities may render patients prone to developing adverse…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].